PubMed Health⌕ Search

Biomedical subjects

N Inaba

Publications and source records attributed to N Inaba.

At least 73 records · Page 4Linked to original sources
PubMed1990

Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay.

Serum placental alkaline phosphatase (PLAP) levels in patients with gynecological tumors were measured by two kinds of enzyme-antigen immunoassay kits provided by Innogenetics (PLAP-I) and Sangtec Medical (PLAP-S), and the combination assays for PLAP with other tumor markers were studied. None of the healthy women studied were PLAP positive, and the positive rate in patients with benign ovarian tumors was less than 6%. The positive rate in patients with ovarian cancers was about 35%, which was higher than the rates for other cancers. It was significantly higher in patients with ovarian serous cystadenocarcinoma (60%). Remarkably high PLAP-I values were observed in patients with dysgerminoma. By the combination assay for PLAP with CA54/61 antigen in ovarian cancers, the diagnostic efficiency increased compared with that for PLAP and CA125. We conclude that PLAP is useful in the diagnosis of ovarian serous cystadenocarcinoma and dysgerminoma and that CA54/61 is the better partner for the combination assay.

Alkaline Phosphatase↗
PubMed1990

Enzyme immunoassay for placental protein 4 (PP4) and its possible diagnostic significance in patients with genital tract cancer.

We have established an enzyme immunoassay for placental protein 4 (PP4), by using avidin-biotin binding reaction, and set its normal range below 10.9 ng/ml (mean + 2 sigma). Throughout the menstrual cycle, the serum PP4 profile was similar to that of serum progesterone. In the follicular and ovulatory phase, PP4 remained relatively low, with the mean levels of 1.5 ng/ml and 1.8 ng/ml, respectively. In the luteal phase, the mean level was 3.2 ng/ml. In normal pregnancy, serum PP4 levels were low irrespective of gestational age, with a mean level of 3.0 ng/ml. There was only one case in which the serum PP4 level over 10.9 ng/ml. Mean serum PP4 levels and the frequencies of elevated serum PP4 levels were respectively 6.3 ng/ml and 11% in patients with benign ovarian neoplasms, 4.7 ng/ml and 6% in patients with endometriosis, and 5.5 ng/ml and 18% in patients with uterine myomata. The frequency of raised PP4 levels was 48% and the mean value was 13.3 ng/ml in patients with endometrial carcinoma, and the values were 44% and 13.4 ng/ml respectively in patients with cervical carcinoma. In patients with ovarian malignancy, the respective values were 15% and 7.0 ng/ml. The results did not relate to clinical stages of disease (FIGO), while the frequencies of elevated serum PP4 in patients with uterine carcinoma was over 40% in stage I diseases. Compared with other tumor markers such as carcino-embryonic antigen (CEA), tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125), PP4 seems to be more promising as a marker of endometrial carcinoma.(ABSTRACT TRUNCATED AT 250 WORDS)

Annexin A5↗
PubMed1990

Immunohistochemical localization and physiological regulation of carbonyl reductase in immature rat ovary.

The present study was performed to clarify the role of the ovarian carbonyl reductase (OCR) in ovarian function in immature rats. The OCR activities towards three specific substrates, 13,14-dihydro-PGF2 alpha, 4-benzoylpyridine and menadione, were photometrically and radiochemically determined in the 9,000 x g supernatants of ovaries, and OCR content was measured by Western-blot-peroxidase anti-peroxidase (PAP) analysis. Immunohistochemical localization of the enzyme in the ovary was performed by the avidin-biotin-complex (ABC) method for paraffin sections. Positive immunoreactivity with OCR antibody was observed for the theca cells and interstitial gland cells at 72 hr after pregnant mare serum gonadotropin (PMSG) treatment when ovulation was confirmed, and the granulosa cells were consistently negatively stained. The OCR activity was significantly increased by PMSG, human chorionic gonadotropin (hCG) and PMSG-hCG treatments, but estradiol and tamoxifen overcame the effect of PMSG on the enzyme activity. Moreover, estradiol enhanced the effect of hCG, but tamoxifen did not. Changes in the OCR activity well-correlated with those in the OCR content. These findings indicate that the OCR is regulated by gonadotropin and estrogen and that metabolites formed by the enzyme could be closely involved in ovarian cell function.

Alcohol Oxidoreductases↗
PubMed1990

Incidence of antibodies against human immunodeficiency virus, human T-cell lymphotropic virus type 1, hepatitis B virus, hemorrhagic fever with renal syndrome virus and Chlamydia in Tonga and western Samoa.

Among the populations of Tonga and Western Samoa, serum antibodies against human immunodeficiency virus or hemorrhagic fever with renal syndrome virus were not detected (0/904 and 0/192). No serum samples were considered to be positive for antibody against human T-cell lymphotropic virus type 1 (0/527). Hepatitis B antigen and antibody were found in 4% (8/192) and 47% (90/192), respectively. Chlamydia trachomatis IgG and C. psittaci IgG antibodies were detected in 39% (75/192) and 47% (91/192), respectively. The possibilities of the spread of human immunodeficiency virus and hemorrhagic fever with renal syndrome virus on the islands when the viruses invade from abroad were discussed.

Adolescent↗
PubMed1990

[Diagnosis: tumor marker].

We have reviewed the clinical usefulness of tumor markers in gynecologic malignancy. In cervical squamous cell carcinoma. SCC and CEA showed increase in frequency of elevated cases according to the clinical stages (FIGO), and the frequency was significantly higher in recurrent cases than in patients with no evidence of disease. In endometrial carcinoma, presently, no specific tumor marker has been found. The diagnostic efficiency of CA 125, CA 19-9 and TPA were 25.2, 23.8 and 32.6, respectively. Further investigation must be necessary to establish markers sensitive enough. In primary ovarian malignancy, combination assay might be much more useful than single assay. The most effective combinations were TPA/CA 125/Ferritin in serous cystadenocarcinoma, and CEA/CA 19-9/TPA in mucinous cystadenocarcinoma. In the monitoring of the disease, it seems to be essential to select suitable combination of markers in each case. In addition, recently, multivariate analysis systems, such as CAMPAS (computer-aided multivariate and pattern analysis system), have become available.

Biomarkers, Tumor↗
PubMed1990

[The treatment of refractory choriocarcinoma].

The choriocarcinoma was one of the most curable malignant neoplasms. This is chiefly because the effective chemotherapy was introduced and the sensitivity of hCG was improved. But about 10-20% cases with choriocarcinoma were drug resistant or recurrent cases. And now, the treatment of these refractory choriocarcinomas were one of the most important clinical problems. We describe a new combination chemotherapy for these refractory choriocarcinomas in this paper. This high dose 5-FU + Act-D protocol was effective for drug resistant cases with MEA protocol.

Adult↗
PubMed1990

[Cell biological characteristics of a human embryonal carcinoma cell line].

We examined the cell biological characteristics of a human embryonal carcinoma cell line. NEC 14, derived from a male germ cell tumor of testis origin. The following results were obtained. 1) The morphological characteristics of NEC 14 cells were small size, an increase in the N/C ratio and poor development of organelle and desmosome-like cell-cell junctions. The NEC 14 cells proliferated rapidly and the population doubling time in vitro was 17 hours. 2) The functional characteristics of NEC 14 cells were the localization of intermediate filaments such as keratin and vimentin, hCG secretion and tissue plasminogen activator and laminin synthesis and expression of cell surface antigens such as stage-specific embryonic antigen-3, trophoblast antigen and neuron cell surface antigen. 3) The mode of chromosome number was 58 and many abnormal and undetermined chromosomes were found in the NEC 14 cells. 4) Differentiation was observed in vitro and in the tumor tissues xenotransplanted into nude mice.

Antigens, Surface↗
PubMed1989

[A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].

Two murine monoclonal antibodies designated 130-22 and 145-9 have been recently established by immunizing mice with a pulmonary carcinoma cell line (PC-9). With use of these monoclonal antibodies a sensitive sandwich immunoradiometric assay (IRMA) for cancer antigen 130 (CA130) was developed in Daiichi Radioisotope Laboratories (Tokyo). Applying this IRMA kit CA130 concentrations were measured in various body fluids with special reference to obstetrics and gynecology. The results are as follows; 1) A CA130-IRMA showed excellent sensitivity, specificity, reproducibility and analytical recovery. The standard dose-response curve covered the range from 10 to 500 U/ml. 2) Serum CA130 levels measured by this assay system were closely correlated with serum CA125 levels, demonstrating quite a high correlation coefficient (r = 0.965). 3) In pregnancy maternal CA130 levels increased moderately (less than 300 U/ml) in the first trimester, and thereafter fell rapidly under normal upper limit (less than 35 U/ml). Immediately after deliveries maternal CA130 levels showed a rapid increase, reaching 269 U/ml (mean levels). In amniotic fluids CA130 concentrations were greatly elevated (3,236 U/ml mean levels), while the levels were almost within normal limit in the umbilical arterial and venous blood. Accordingly it is necessary to measure Schwangerschaftsprotein 1 or human chorionic gonadotropin simultaneously with CA130 to rule out possible pregnancy. 4) CA130 was clearly localized in the amniotic epithelium and umbilical sheath and other placental tissue components remained negative for this antigen. Taking the lower CA130 levels in the umbilical sera into consideration, these immunohistochemical results suggest CA130 is not oncofetal but oncoplacental. 5) Serum CA130 levels increased pretherapeutically beyond 35 U/ml in 87% of ovarian malignancies, and in 56% of endometrial carcinoma. The mean levels of serum CA130 reached 931 and 143 U/ml, respectively. These data indicate clinical usefulness of CA130 as a tumor marker for those diseases. By contrast serum CA130 levels were lower, and very few cases showed serum CA130 levels over 35 U/ml in cervical cancer. 6) In endometriosis 88% of the cases demonstrated increased serum CA130 levels, indicating its usefulness for monitoring therapeutic courses, just like CA125. In benign gynecologic diseases over 80% of cases showed increased serum CA130 levels while only slight increase in serum CA130 was found (mean levels less than 84.0 U/ml). This disadvantage could be lessened by a combination assay with CA72-4 and others whose serum levels were very low in the benign diseases.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1989

Detection of the human papillomavirus 6b E2 gene product in genital condyloma and laryngeal papilloma tissues.

We have previously reported that the E2 open reading frame of human papillomavirus type 6b (HPV6b) was expressed in Bombyx mori cell line Bm-N as a fusion protein with baculovirus polyhedrin. Here we show that antibody against this E2-polyhedrin fusion protein recognized a putative gene product as a 49-kDa protein in some genital condyloma and laryngeal papilloma tissues, which were associated with HPV6 and HPV11, by immunoblotting analysis. The antibody reacted also with antigens in the nucleus of cells in the middle and upper layers of these papilloma tissues.

Animals↗
PubMed1989

Clinical significance of a solid-phase immunoradiometrical assay for sialyl SSEA-1 antigen in obstetrics and gynecology.

The clinical usefulness of sialyl SSEA-1 antigen was evaluated in obstetrics and gynecology. Serum levels of sialyl SSEA-1 were measured in patients with benign or malignant gynecologic diseases, and in normal pregnant women. Moreover, in 10 cases of full term delivery, samples of maternal sera immediately prior to delivery, soon after delivery and 5-day-puerperium, cord sera from the umbilical artery and vein, and amniotic fluid were taken to measure its concentration. During the course of pregnancy, serum SSEA-1 levels were within the normal range (below 38 U/ml), showing no significant correlation with gestational weeks. Of patients with gynecologic diseases, those with malignant ovarian neoplasms, uterine cervical carcinoma and benign ovarian neoplasms exhibited elevated (over 38 U/ml) levels in 26%, 15% and 6% of all cases, respectively. In cases of full term delivery, the concentrations of sialyl SSEA-1 in the maternal and cord sera were within the normal range. Concentrations were extremely high, however, in the amniotic fluid.

Amniotic Fluid↗
PubMed1989

Immunochemical measurement and immunohistochemical detection of membrane-associated placental tissue protein 1.

Using the avidin-biotin binding system, an enzyme immunoassay procedure was developed to measure the membrane-associated placental tissue protein 1 (MP1) in serum. The standard curve covered the range from 10 to 1000 ng/ml of MP1. The intra- and inter-assay coefficient of variations (C.Vs) were less than 5 and 10%, respectively. Recoveries of MP1 added to serum ranged between about 96 and 101%. The MP1 serum level was over 10 and under 112 ng/ml in non-pathological men, and under 240 ng/ml in non-pathological women. The MP1 level in the ovulatory phase was higher than in other phases of the menstrual cycle. In pregnancies during 6-39 weeks, the MP1 level ranged from 10 to 540 ng/ml, and it increased during the third trimester of gestational age. In benign gynecologic diseases, the MP1 concentration in serum ranged from 10 to 215 ng/ml. The MP1 levels in benign diseases were compared with those in ovarian malignancies, in endometrial carcinoma, and in uterine cervical cancer. The immunohistochemical location of MP1 was detected in the cell membrane of ovarian cystadenocarcinoma.

Female↗
PubMed1989

[Resistance to anticancer drugs in relation to cytochrome P-450].

Cytochrome p-450 is a product of a multigene family, and catalyzes the activation and the detoxication of a wide variety of exogenous as well as endogenous compounds. Recent studies have the purified forms of cytochrome p-450 and provided evidence that some anticancer agents are metabolically activated by the cytochrome. In general, cancer cells express lower amounts of cytochrome p-450 as compared to normal liver cells. We recently succeeded in purifying P-450 HFLa, a form of cytochrome P-450 in human fetal livers. Examinations using antibodies to P-450 HFLa, however, showed that proteins cross-reactive with antibodies to P-450 HFLa existed in gynecologic malignancies. Development of multiple drug resistance is usually associated with a decrease in the content of cytochrome P-450, which is in contrast with glutathione S-transferase and a few other enzymes. The mechanisms responsible for such altered enzyme activity by multiple drug resistance are unclear as yet.

Animals↗
PubMed1989

Physiological role of ovarian carbonyl reductase and effect of antiestrogen on its activity in rats.

In order to clarify physiological role of carbonyl reductase in rat ovary and effect of antiestrogen on its activity, we investigated effects of five antiestrogens on changes in ovarian enzyme activities towards three carbonyl compounds. All of five antiestrogens tested, significantly decreased 13,14-dihydro-15-ketoprostaglandin F2 alpha 4-benzoylpyridine and menadione reducing activities in ovarian cytosol by both consecutive treatments and single treatment. This inhibition of ovarian enzyme activities by antiestrogen was dramatically antagonized by human chorionic gonadotropin treatment at 3:00 p.m. on the day of proestrus. These results suggest that antiestrogen inhibits LH surge at afternoon of proestrus in rats and that the ovarian enzyme catalyzing reduction of carbonyl compounds is involved in ovulatory process.

Alcohol Oxidoreductases↗
PubMed1989

[The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].

The clinical usefulness of a newly developed one-step enzyme-immunoassay, MKS-15, in the diagnosis of ovarian cancer was evaluated with 1,563 serum samples collected at five institutes. In this assay, two monoclonal antibodies, MA54 and MA61, which both recognize the carbohydrate chain in a high molecular weight mucin-type glycoprotein, were used as the immobilized antibody on beads and peroxidase-labeled antibody, respectively. When the cut-off value was set at 20 IU/ml (mean + 3SD), 56% of the sera from ovarian cancer patients were positive, and the positive rates for serous, mucinous, mesonephroid, endometrioid, undifferentiated, and metastatic cancers were 63%, 55%, 52%, 38%, 55%, and 62%, respectively. In sera from patients with benign ovarian tumors, only 4% of the cases were positive, but 7% of benign and low potential malignant cases of mucinous cystadenoma were positive, indicating that CA54/61 cannot distinguish benign mucinous cystadenoma from malignant ones. Since the positive rate for CA125 is rather low in mucinous cyst-adenocarcinoma, CA54/61 may be of clinical value.

Adolescent↗
PubMed1989

[Diagnosis of precancerous lesions of the endometrium].

Cytodiagnosis of the precancerous lesions of the endometrium has remained unclear compared to that for cervical lesions. Endometrial cytology and biopsy have been performed for patients with atypical genital bleeding, who were over fifty, postmenopausal or nulliparous, We studied cytologic findings in cystic glandular, adenomatous and atypical hyperplasia, and compared to them in early cancer. Differential diagnosis was somewhat difficult between cystic glandular hyperplasia and benign lesions. Cytological diagnosis becomes gradually easier with progress of the lesions. A few cases with endometrial hyperplasia developed endometrial carcinoma for several years. Endometrial carcinoma has been detected even in the patients with suspicious endometrial cytology, so endometrial biopsy is still an important method. However, endometrial cytology is very easy, so we need to clarify the cytological cytological characteristics in precancerous lesions of the endometrium.

Cytodiagnosis↗
PubMed1988

Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.

We studied immunohistochemical stains for TPA and CA125 in patients with benign and malignant gynecologic diseases. The results were as follows: (1) CA125 was not found in ovarian mucinous cystadenocarcinoma but was demonstrated immunohistochemically in 82% of ovarian serous cystadenocarcinomas and 83% of Krukenberg's tumors. (2) TPA was demonstrated in 65% of ovarian serous and 75% of ovarian mucinous cystadenocarcinomas, and in 58% of endometrial carcinomas. (3) TPA was found in all trophoblastic tumors examined, while CA125 was found in none. Eighty-three percent of patients with trophoblastic diseases had raised serum TPA levels. (4) When serum CA125 levels were raised CA125 was demonstrated immunohistochemically in 71% of patients with ovarian serous cystadenocarcinomas, 67% of patients with Krukenberg's tumors and 100% of patients with tubal carcinomas. (5) Despite elevated serum levels, CA125 and TPA were not identified by immunohistochemistry in 64% cases of benign ovarian disease and in 80% of patients with uterine myomata. (6) It would seem that CA125 was more easily released from tumor cells than TPA.

Antigens, Neoplasm↗
PubMed1988

Immunohistochemical study of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) in the human and cynomolgus monkey placenta, umbilical cord and decidua.

Tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) were studied immunohistochemically by the avidin-biotin immunoperoxidase technique in human and cynomolgus monkey placentae, membranes, umbilical cords and decidua. In early human placentae, TPA was localized mainly in the cell membranes of villous syncytio- and cyto-trophoblast. The cytoplasm of those trophoblastic cells were weakly stained with TPA. The membrane of basal chorionic trophoblast cells was strongly stained with TPA and the cytoplasm stained weakly. In early cynomolgus placentae, similar immunostaining results were obtained. However, the positive stainings for TPA was more marked in the cytoplasm of villous syncytiotrophoblast and basal chorionic trophoblast, and less marked in the cell membrane of villous cytotrophoblast. In early human and cynomolgus placentae, CA125 was not demonstrated immunohistochemically in the villi and basal chorion. In human and cynomolgus term placentae, the villous syncytiotrophoblast and basal and reflected chorionic trophoblast showed similar immunostaining as the early placentae. In addition, TPA was found in the amniotic epithelium in both sorts of placentae. TPA was not detected immunohistochemically in the umbilical cord and decidual cells. While weakly positive stains for CA125 were observed in decidual cells, CA125 was localized mainly in the membrane and cytoplasm of amniotic epithelium in both human and cynomolgus term placentae. TPA and CA125 are thus oncoplacental antigens and the monkey could serve as a model for their investigation.

Animals↗